research use only

Etoricoxib COX inhibitor

Name: Etoricoxib
Brand: Selleck Chemicals
SKU: S4651
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S4651

Etoricoxib (Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia) is a new COX-2 selective inhibitor with anti-inflammatory, antipyretic, analgesic, and potential antineoplastic properties.

Chemical Structure

Molecular Weight: 358.84

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S465101 DMSO]71 mg/mL]false]Ethanol]46 mg/mL]false]Water]Insoluble]false Purity: 99.61%

99.61

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel GluR MAO Beta Amyloid NMDAR P2 Receptor Trk receptor Serotonin Transporter Notch Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor BChE Adenosine Deaminase CCK receptor MT Receptor
Related Products	NS-398 (NS398) Paeoniflorin (NSC 178886) Lumiracoxib Xanthohumol Bufexamac Oroxin B Tolfenamic Acid Nimesulide Ginsenoside Rd Indometacin Sodium Pranoprofen (-)-Epicatechin gallate Salicin SC-560 Triflusal Phenacetin (+/-)-Sulfinpyrazone (+)-Catechin hydrate Niflumic acid 4-Hydroxyphenylpyruvic acid 3-Carene Rutaecarpine Fenbufen Licofelone (ML3000)

Chemical Information, Storage & Stability

Molecular Weight	358.84	Formula	C₁₈H₁₅ClN₂O₂S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	202409-33-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia			Smiles	CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C

Solubility

In vitro
Batch:

DMSO : 71 mg/mL ( (197.85 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 46 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.55mg/ml (9.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 71 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.51mg/ml (1.42mM)	Taking the 1 mL working solution as an example, add 50 μL of 10.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	COX-2 ^[1]
In vivo	The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model^[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon^[2].
References	https://pubmed.ncbi.nlm.nih.gov/20609063/ https://pubmed.ncbi.nlm.nih.gov/21198287/ https://pubmed.ncbi.nlm.nih.gov/18711209/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05142098	Unknown status	Effect of Drug	Dow University of Health Sciences	January 1 2022	Early Phase 1
NCT05791721	Completed	Surgical Wound\|Post Operative Pain	University of Belgrade	October 11 2021	Phase 4
NCT02503839	Completed	Tuberculosis	Anne Margarita Dyrhol Riise\|University of Oslo\|Statens Serum Institut\|Haukeland University Hospital\|Oslo University Hospital	November 2015	Phase 1
NCT02568735	Completed	Pain Postoperative	Kuopio University Hospital	January 2013	Phase 4
NCT01572675	Completed	Osteoarthritis	Organon and Co	June 2012	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):